ArticleBMC cardiovascular disorders2025
The potential value of microRNA-409-5p-mediated negative regulation of USP7 in the diagnosis and treatment of acute myocardial infarction.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thrombin concentration shapes endothelial extracellular vesicle profiles with divergent inflammatory functions.Blood advances · 2026Article
- Clinical significance of lncRNA GAS5 in deep vein thrombosis and its mechanism of action on vascular endothelial damage.BMC cardiovascular disorders · 2026Article
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThis study aimed to explore the effects of ubiquitin-specific peptidase 7 (USP7) on acute myocardial infarction (AMI) and the negative regulation of USP7 by microRNA-409-5p (miR-409-5p).
methodsClinical data were collected from patients admitted to the Cardiology Department of Yan'an Hospital of Kunming City between July 2020 and July 2021. The participants included patients with AMI (AMI; n = 30), stable angina pectoris (SAP; n = 30), and chest pain syndrome (CPS; n = 30) and healthy controls (n = 30). The expression levels of miR-409-5p and USP7 were analysed using Quantitative real-time polymerase chain reaction (qRT‒PCR) and Western blotting (WB). Finally, a dual-luciferase assay was performed to verify the interaction between miR-409-5p and USP7.
resultsThe expression level of miR-409-5p was significantly lower (all p < 0.05), whereas the expression level of USP7 was elevated in patients with AMI compared with those in the other three groups (all p < 0.05). A dual-luciferase assay demonstrated that miR-409-5p binds to USP7 3'UTP to inhibit luciferase expression. Compared with cells transfected with mutation fragments and a luciferase reporter vector with microRNA-409-5p mimics and USP7 3'UTR binding and mutation sites, the luminescence level of cells with miR-409-5p was approximately 40% lower. Additionally, miRNA-409-5p was inversely correlated with cTnI (p = 0.004).
conclusionUSP7 plays a significant role in AMI via negative regulation by miR-409-5p. Both miR-409-5p and USP7 hold key potential as early diagnostic biomarkers and therapeutic targets for AMI in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.